<DOC>
	<DOCNO>NCT00813748</DOCNO>
	<brief_summary>This study establish clinical data serum repository anaphylaxis case associate Xolair administration control patient receive Xolair without associate anaphylaxis . This observational repository investigational clinical trial . Associated repository optional skin test substudy .</brief_summary>
	<brief_title>Pharmacosurveillance Data Repository Patients With Without History Anaphylactic Reactions Subsequent Xolair Dosing</brief_title>
	<detailed_description />
	<mesh_term>Anaphylaxis</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion Criteria Cases : Confirmed anaphylaxis base Sampson criterion subsequent Xolair Inclusion Criteria Controls : At least 1 patient control among 4 control discontinue Xolair least 16 week 18 month enrollment At least one dose Xolair 18 month date case event ( index date ) No prior anaphylaxis hypersensitivity reaction subsequent Xolair dosing , include reaction component</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Anaphylaxis</keyword>
</DOC>